Cancer News and Research

Latest Cancer News and Research

Arizona Republic examines health insurance policy rescissions

The Arizona Republic on Friday examined how the practice of health insurers rescinding and canceling the health care policies of beneficiaries has been "scrutinized from California to Connecticut with some states passing tough measures or pursuing regulatory actions and assessing fines to restrict these retroactive health policy voids."

2 Jun 2008

Study looks at the role of metformin as possible anti-tumor agent

Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing pathologic complete response rates in diabetic women with early stage breast cancer who took the drug during chemotherapy prior to having surgery, paving the way for further research of the drug as a potential cancer therapy, according to researchers at The University of Texas M. D. Anderson Cancer Center.

2 Jun 2008

Chronic inflammation of the intestine or stomach damages DNA

Chronic inflammation of the intestine or stomach can damage DNA, increasing the risk of cancer, MIT scientists have confirmed.

2 Jun 2008

Celldex Therapeutics vaccine may double survival in patients with deadly brain tumors

A vaccine aimed at inducing immunity to the most common and deadly type of brain tumor may stave off recurrence and more than double survival in patients, according to a new study led by researchers in Duke's Preston Robert Tisch Brain Tumor Center.

2 Jun 2008

New approach to treating autoimmune disease offered by Weizmann scientists

In autoimmune diseases, the immune system turns against the body's own tissues and organs, wreaking havoc and destruction for no apparent reason. Partly because the origins of these diseases are so obscure, no effective treatment exists, and the suffering they inflict is enormous.

2 Jun 2008

Gemcitabine with bevacizumab and radiotherapy safe for pancreatic cancer patients

Treating pancreatic cancer with a combination of chemotherapy, biotherapy and radiotherapy prior to surgery is safe and may be beneficial for patients, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

2 Jun 2008

Distinct clusters of genetic markers linked to treatment responses for smoking cessation

Scientists have identified distinct clusters of genetic markers associated with the likelihood of success or failure of two smoking cessation treatments, nicotine replacement therapy (NRT) and the medication bupropion (Zyban). This study, supported by the National Institute on Drug Abuse (NIDA) and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), was published in the June issue of the journal Archives of General Psychiatry.

2 Jun 2008

New model predicts whether patients will be free of renal cancer 12 years after initial treatment

A UT Southwestern Medical Center physician and other researchers have developed a unique statistical model that predicts the probability of a patient being cancer free 12 years after initial surgical treatment.

2 Jun 2008

Improving palliative care

Palliative care clinicians are increasingly faced with the problem of treating a wider range of diseases, and treating patients in all settings, not just in hospices or specialist units. This has created new challenges in the treatment of symptoms, which in turn creates a need for new research and practical recommendations to help palliative care clinicians and improve patient care.

2 Jun 2008

New breast cancer drug combo shrinks aggressive tumours

An international trial of a new breast cancer drug has shown the drug is able to shrink tumours caused by one of the most aggressive forms of the disease.

2 Jun 2008

Peregrine Pharmaceuticals updates on Bavituximab breast cancer study

Peregrine Pharmaceuticals, Inc. has announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

2 Jun 2008

Oncolytics Biotech announces results for intravenous Reolysin in patients with sarcomas metastatic to the lung

Oncolytics Biotech Inc. has announced that interim results of a Phase II study of intravenous Reolysin in patients with sarcomas metastatic to the lung were presented yesterday at the American Society of Clinical Oncology (ASCO) annual meeting.

2 Jun 2008

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex, Inc. has announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody.

2 Jun 2008

IDM Pharma presents new data on IDM-2101 in non-small cell lung cancer

IDM Pharma, Inc. today announced follow-up results from the Phase 2 study of IDM-2101 showing that the product candidate was well tolerated, induced broadly specific cytotoxic T lymphocyte (CTL) responses, and showed a positive survival trend in HLA-A2 positive patients with non-small cell lung cancer (NSCLC) who were treated with IDM-2101, compared to a parallel external control group of HLA-A2 negative non-treated patients.

2 Jun 2008

BiPar Sciences presents data for novel DNA repair inhibitor

BiPar Sciences, Inc. today announced the results of first-in-human clinical studies of its lead product, BSI-201, in patients with solid tumors.

2 Jun 2008

Genta announces initial trial results for novel drug for bone disease

Genta Incorporated has announced the release of final results from the Company's Phase 1 clinical trial of G4544, a proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. Results showed that the drug was very well-tolerated, and that blood levels were achieved in a range that is known to be clinically bioactive. The data were featured in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 31, 2008.

2 Jun 2008

Royal seal of approval for Breakthrough Breast Cancer's world-class research unit in Edinburgh

A pioneering new breast cancer research unit set up by leading UK charity Breakthrough Breast Cancer and the University of Edinburgh will be officially opened on Thursday 5 June 2008 by HRH The Prince of Wales (also known as The Duke of Rothesay while travelling in Scotland), the charity's Patron.

2 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.

2 Jun 2008

Survivors of childhood Hodgkin's lymphoma at higher risk of future health problems

Adults who survived childhood Hodgkin's Lymphoma should be especially vigilant about cancer and cardiovascular screenings, according to researchers from Wake Forest University Baptist Medical Center and colleagues.

2 Jun 2008

Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s

The prevalence of pre-cancerous masses in the colon is the same for average-risk patients who are 40 to 49 years of age and those who are 50 to 59 years of age, reports a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

2 Jun 2008

Cancer News and Research

Latest Cancer News and Research

Arizona Republic examines health insurance policy rescissions

Study looks at the role of metformin as possible anti-tumor agent

Chronic inflammation of the intestine or stomach damages DNA

Celldex Therapeutics vaccine may double survival in patients with deadly brain tumors

New approach to treating autoimmune disease offered by Weizmann scientists

Gemcitabine with bevacizumab and radiotherapy safe for pancreatic cancer patients

Distinct clusters of genetic markers linked to treatment responses for smoking cessation

New model predicts whether patients will be free of renal cancer 12 years after initial treatment

Improving palliative care

New breast cancer drug combo shrinks aggressive tumours

Peregrine Pharmaceuticals updates on Bavituximab breast cancer study

Oncolytics Biotech announces results for intravenous Reolysin in patients with sarcomas metastatic to the lung

Medarex announces preliminary data for investigational anti-PD-1 antibody

IDM Pharma presents new data on IDM-2101 in non-small cell lung cancer

BiPar Sciences presents data for novel DNA repair inhibitor

Genta announces initial trial results for novel drug for bone disease

Royal seal of approval for Breakthrough Breast Cancer's world-class research unit in Edinburgh

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

Survivors of childhood Hodgkin's lymphoma at higher risk of future health problems

Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s

Industry Focus eBook: Oncology eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook: Oncology eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in